Artesunate has been used worldwide for many years and is recommended by the World Health Organization for the treatment of severe malaria. However, data indicates IV Vitamin C (IVC) in conjunction with IV Artesunate makes a substantial difference in advanced cancers.
IV Artesunate often is administered right before high dose IV Vitamin C and there is evidence that these therapies work synergistically together. In patients with Stage IV breast cancer, after one year the group that received no IVC and IV Artesunate had a 74 percent survival rate — compared to the IVC and IV Artesunate group which had a 90 percent survival rate after one year.
By year 2 the results were even more significant: The group that did not receive treatment had a 68 percent survival rate compared to 90 percent in the treatment group. 
It is also important to note that no adverse events were associated with this treatment.
Clinics that offer
Cancer Tutor Verified
Artesunate administered with IVC provides significant advantages for improved survival, improved tumor sensitivity to chemotherapy, reduced side effects of chemo, and improved energy, appetite, and quality of life.
Artesunate also has been analyzed for its anti-cancer activity against 55 cell lines of the Developmental Therapeutics Program of the National Cancer Institute.
Artesunate was most active against leukemia and colon cancer cell lines. Non-small cell lung cancer cell lines showed the highest mean GI50 value, indicating the lowest sensitivity toward artesunate in this test panel. Intermediate GI50 values also were obtained for melanomas, breast, ovarian, prostate, CNS, and renal cancer cell lines. 
Artemisinin and its derivatives dihydroartemisinin and artesunate were researched in 2010 for its anti-cancer activity. In a panel of chemosensitive and chemoresistant human neuroblastoma cells as well as in primary neuroblastoma cultures, artesunate was proven more active in affecting neuroblastoma cell viability.
Artesunate also has been shown to induce oncosis-like cell death in vitro and has anti-tumor activity against pancreatic cancer xenografts in vivo. 
In 2015, results were published from a double-blind pilot study of oral artesunate therapy for colorectal cancer. It concluded larger clinical studies with artesunate should be implemented and may provide an intervention where none is currently available, as well as synergistic benefits with current regimens.